MUTUAL CONFIDENTIALITY AGREEMENTMutual Confidentiality Agreement • August 20th, 2024 • Pharmacosmos a/S • Pharmaceutical preparations
This Mutual Confidentiality Agreement (the ”Agreement”), effective as of February 6, 2024 (the “Effective Date”), by and between Pharmacosmos A/S, company registration number 15517085, located at Rørvangsvej 30, DK-4300 Holbæk, Denmark (“Pharmacosmos“) and G1 Therapeutics, Inc., located at 700 Park Offices Drive, Suite 200, Research Triangle Park, North Carolina 27709 USA (“G1 Therapeutics”). Pharmacosmos and G1 Therapeutics are each referred to herein as a “Party” and collectively as the “Parties”.
August 6, 2024 G1 Therapeutics, Inc.Exclusivity Agreement • August 20th, 2024 • Pharmacosmos a/S • Pharmaceutical preparations
27P5-UN7U-HHNAOperating Credit Agreement • August 20th, 2024 • Pharmacosmos a/S • Pharmaceutical preparations
Please note that this document is an English translation of the original Danish version prepared only for your convenience. In the case of any discrepancy between the translation and the Danish original, the latter shall prevail.
AMENDMENT NO. 1 TO MUTUAL CONFIDENTIALITY AGREEMENTMutual Confidentiality Agreement • August 20th, 2024 • Pharmacosmos a/S • Pharmaceutical preparations
This Amendment No. 1 to Mutual Confidentiality Agreement (the “Amendment”) is entered into by and between G1 Therapeutics, Inc., a Delaware corporation (“G1 Therapeutics”) and Pharmacosmos A/S (“Pharmacosmos”) and is effective as of July 11, 2024 (the “Effective Date”).
